Stock comparison
Camurus AB (publ)
CAMX.ST$36.93BHealthcare Market cap, Sector
Theravance Biopharma
TBPH$872.79MHealthcare Market cap, Sector
Overall winner
Camurus AB (publ)
CAMX.ST 70 TBPH
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
Fit scores by strategy
CAMX.ST7wins
0winsTBPH
78B
D53
91A
D51
94A
D45
65C
D53
63C
F36
77B
F39
77B
D56
Side-by-side metrics
| Metric | CAMX.ST | TBPH |
|---|---|---|
| Market cap | Winner: $36.93B | $872.79M |
| P/E (TTM) | 42.6x | 7.4x Winner |
| EV/EBIT | 29.5x | - Winner |
| ROIC (TTM) | Winner: 17.17% | -1.32% |
| Gross margin | 93.11% | 104.1% Winner |
| Net margin | 32.47% | 104.34% Winner |
| Revenue CAGR 5y | Winner: 33.3% | 18.06% |
| EPS CAGR 5y | 132.79% | - |
| Debt / Equity | Winner: 0.0x | 0.3x |
| Dividend yield | - | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
CAMX.ST leads on
- ROIC (TTM)17.17%vs -1.32%+108%
- Market cap$36.93Bvs $872.79M+98%
- Debt / Equity0.0xvs 0.3x+90%
- Revenue CAGR 5y33.3%vs 18.06%+46%
TBPH leads on
- EV/EBIT-vs 29.5x+162%
- P/E (TTM)7.4xvs 42.6x+83%
- Net margin104.34%vs 32.47%+69%
- Gross margin104.1%vs 93.11%+11%
More like CAMX.ST
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.